About: Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study.     Goto   Sponge   Distinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • PURPOSE: Bmi-1 is a Polycomb group member which participates in many physiological processes as well as in a wide spectrum of cancers. The aim of this study was to investigate Bmi-1 expression in non-small cell lung cancer (NSCLC) in respect to clinicopathological features and therapeutic outcomes. METHODS: Immunohistochemical staining for Bmi-1 was performed on tissue microarrays (TMAs) constructed from 179 formalin-fixed and paraffin-embedded NSCLC samples (106 squamous, 58 adeno-, and 15 large cell carcinomas). Data were subject to statistical analysis by SPSS. RESULTS: Overall evaluation of all tumor cases showed that 20 (11.43%) were negative, 37 (21.14%) showed weak, 65 (37.14%) moderate and 57 (32.57%) strong nuclear positivity for Bmi-1. Statistical analysis of our data revealed that the expression of Bmi-1 was significantly higher in stage III (P = 10(-6)) and stage IV (P = 10(-5)) tumors compared to stages I and II tumors. The administration of adjuvant chemotherapy significantly increased D
  • PURPOSE: Bmi-1 is a Polycomb group member which participates in many physiological processes as well as in a wide spectrum of cancers. The aim of this study was to investigate Bmi-1 expression in non-small cell lung cancer (NSCLC) in respect to clinicopathological features and therapeutic outcomes. METHODS: Immunohistochemical staining for Bmi-1 was performed on tissue microarrays (TMAs) constructed from 179 formalin-fixed and paraffin-embedded NSCLC samples (106 squamous, 58 adeno-, and 15 large cell carcinomas). Data were subject to statistical analysis by SPSS. RESULTS: Overall evaluation of all tumor cases showed that 20 (11.43%) were negative, 37 (21.14%) showed weak, 65 (37.14%) moderate and 57 (32.57%) strong nuclear positivity for Bmi-1. Statistical analysis of our data revealed that the expression of Bmi-1 was significantly higher in stage III (P = 10(-6)) and stage IV (P = 10(-5)) tumors compared to stages I and II tumors. The administration of adjuvant chemotherapy significantly increased D (en)
  • Cíl: Bmi-1 je člen polykomb. skupiny, ktrá se účastní mnoha fyziologických procesů, stejně jako v širokém spektru druhů rakoviny. Cílem této studie bylo prozkoumat Bmi-1 expresi u nemalobuněčné rakoviny plic (NSCLC) s ohledme na klinickopatologické znaky a terapeutické závěry. (cs)
Title
  • Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study.
  • Prognostická hodnota Bmi-1 onkoproteinové exprese u NSCLC pacientů: a tissue microarray study. (cs)
  • Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. (en)
skos:prefLabel
  • Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study.
  • Prognostická hodnota Bmi-1 onkoproteinové exprese u NSCLC pacientů: a tissue microarray study. (cs)
  • Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. (en)
skos:notation
  • RIV/61989592:15110/08:00006169!RIV09-MZ0-15110___
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • P(NR8370), P(NR8425), S, Z(MSM6198959216)
http://linked.open...iv/cisloPeriodika
  • 1
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 390192
http://linked.open...ai/riv/idVysledku
  • RIV/61989592:15110/08:00006169
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • Prognostic value of Bmi-1 oncoprotein expression (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • DE - Spolková republika Německo
http://linked.open...ontrolniKodProRIV
  • [3EF3BCA5A4A4]
http://linked.open...i/riv/nazevZdroje
  • Journal of cancer research and clinical oncology
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...vavai/riv/projekt
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 1
http://linked.open...iv/tvurceVysledku
  • Ehrmann, Jiří
  • Hajdúch, Marián
  • Radová, Lenka
  • Vrzalíková, Kateřina
  • Kolář, Zdeněk
  • Klein, Jiří
  • Škarda, Jozef
  • Kolek, Vitězslav
  • Knížetová, Petra
  • Fridman, E.
  • Kopolovic, J.
  • Murray, P. G.
http://linked.open...n/vavai/riv/zamer
issn
  • 0171-5216
number of pages
http://localhost/t...ganizacniJednotka
  • 15110
is http://linked.open...avai/riv/vysledek of
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 117 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software